WO2023060089A3 - Transposases and uses thereof - Google Patents

Transposases and uses thereof Download PDF

Info

Publication number
WO2023060089A3
WO2023060089A3 PCT/US2022/077549 US2022077549W WO2023060089A3 WO 2023060089 A3 WO2023060089 A3 WO 2023060089A3 US 2022077549 W US2022077549 W US 2022077549W WO 2023060089 A3 WO2023060089 A3 WO 2023060089A3
Authority
WO
WIPO (PCT)
Prior art keywords
domains
transposase
transposase domains
transposases
well
Prior art date
Application number
PCT/US2022/077549
Other languages
French (fr)
Other versions
WO2023060089A2 (en
Inventor
Dongyang Zhang
Blair B. MADISON
Joseph S. LUCAS
Olga BATALOV
J. Andres VALDERRAMA
Original Assignee
Poseida Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics, Inc. filed Critical Poseida Therapeutics, Inc.
Priority to CN202280080288.0A priority Critical patent/CN118369422A/en
Priority to IL311782A priority patent/IL311782A/en
Priority to AU2022358729A priority patent/AU2022358729A1/en
Priority to JP2024519988A priority patent/JP2024536307A/en
Priority to CA3234642A priority patent/CA3234642A1/en
Priority to EP22798022.4A priority patent/EP4413124A2/en
Priority to KR1020247014862A priority patent/KR20240099249A/en
Priority to US18/696,129 priority patent/US20240392262A1/en
Publication of WO2023060089A2 publication Critical patent/WO2023060089A2/en
Publication of WO2023060089A3 publication Critical patent/WO2023060089A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

This disclosure generally relates to transposase domains, in particular, transposase domains comprising amino terminal deletions, as well as transposase domains forming obligate heterodimers and transposase domains comprising DNA targeting domains.
PCT/US2022/077549 2021-10-04 2022-10-04 Transposases and uses thereof WO2023060089A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202280080288.0A CN118369422A (en) 2021-10-04 2022-10-04 Transposase and use thereof
IL311782A IL311782A (en) 2021-10-04 2022-10-04 Transposases and their uses
AU2022358729A AU2022358729A1 (en) 2021-10-04 2022-10-04 Transposases and uses thereof
JP2024519988A JP2024536307A (en) 2021-10-04 2022-10-04 Transposases and their uses
CA3234642A CA3234642A1 (en) 2021-10-04 2022-10-04 Transposases and uses thereof
EP22798022.4A EP4413124A2 (en) 2021-10-04 2022-10-04 Transposases and uses thereof
KR1020247014862A KR20240099249A (en) 2021-10-04 2022-10-04 Transposase and its uses
US18/696,129 US20240392262A1 (en) 2021-10-04 2022-10-04 Transposase and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163252028P 2021-10-04 2021-10-04
US63/252,028 2021-10-04
US202263312928P 2022-02-23 2022-02-23
US63/312,928 2022-02-23
US202263369863P 2022-07-29 2022-07-29
US63/369,863 2022-07-29

Publications (2)

Publication Number Publication Date
WO2023060089A2 WO2023060089A2 (en) 2023-04-13
WO2023060089A3 true WO2023060089A3 (en) 2023-05-25

Family

ID=84045028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/077549 WO2023060089A2 (en) 2021-10-04 2022-10-04 Transposases and uses thereof

Country Status (8)

Country Link
US (1) US20240392262A1 (en)
EP (1) EP4413124A2 (en)
JP (1) JP2024536307A (en)
KR (1) KR20240099249A (en)
AU (1) AU2022358729A1 (en)
CA (1) CA3234642A1 (en)
IL (1) IL311782A (en)
WO (1) WO2023060089A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024233804A1 (en) 2023-05-10 2024-11-14 Poseida Therapeutics, Inc. Transposases and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140250A1 (en) * 2012-03-23 2013-09-26 Cellectis Method to overcome dna chemical modifications sensitivity of engineered tale dna binding domains
WO2020250181A1 (en) * 2019-06-11 2020-12-17 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same
US20210292773A1 (en) * 2019-04-08 2021-09-23 Dna Twopointo Inc. Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
US5827729A (en) 1996-04-23 1998-10-27 Advanced Tissue Sciences Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
EP3184632B1 (en) 2009-02-26 2024-04-03 Poseida Therapeutics, Inc. Hyperactive piggybac transposases
US10041077B2 (en) 2014-04-09 2018-08-07 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
CN111094407B (en) 2017-09-05 2022-08-30 东丽株式会社 Fiber-reinforced thermoplastic resin molded article
MX2020009309A (en) 2018-03-07 2021-01-08 Poseida Therapeutics Inc Cartyrin compositions and methods for use.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140250A1 (en) * 2012-03-23 2013-09-26 Cellectis Method to overcome dna chemical modifications sensitivity of engineered tale dna binding domains
US20210292773A1 (en) * 2019-04-08 2021-09-23 Dna Twopointo Inc. Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias
WO2020250181A1 (en) * 2019-06-11 2020-12-17 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMMAR ISMAHEN ET AL: "Retargeting transposon insertions by the adeno-associated virus Rep protein", NUCLEIC ACIDS RESEARCH, vol. 40, no. 14, 1 August 2012 (2012-08-01), GB, pages 6693 - 6712, XP093012650, ISSN: 0305-1048, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413126/pdf/gks317.pdf> DOI: 10.1093/nar/gks317 *
CHEN QIUJIA ET AL: "Structural basis of seamless excision and specific targeting by piggyBac transposase", NATURE COMMUNICATIONS, vol. 11, no. 1, 10 July 2020 (2020-07-10), XP055783374, Retrieved from the Internet <URL:http://www.nature.com/articles/s41467-020-17128-1> DOI: 10.1038/s41467-020-17128-1 *
CLAUDIA KETTLUN ET AL: "Manipulating piggybac Transposon chromosomal integration site selection in human cells", MOLECULAR THERAPY, vol. 19, no. 9, 1 January 2011 (2011-01-01), pages 1636 - 1644, XP055768160 *
MORELLET NELLY ET AL: "Sequence-specific DNA binding activity of the cross-brace zinc finger motif of the piggyBac transposase", NUCLEIC ACIDS RESEARCH, vol. 46, no. 5, 27 January 2018 (2018-01-27), GB, pages 2660 - 2677, XP055782782, ISSN: 0305-1048, Retrieved from the Internet <URL:https://academic.oup.com/nar/article-pdf/46/5/2660/24387959/gky044.pdf> DOI: 10.1093/nar/gky044 *
SANDOVAL-VILLEGAS NICOLÁS ET AL: "Contemporary Transposon Tools: A Review and Guide through Mechanisms and Applications of Sleeping Beauty, piggyBac and Tol2 for Genome Engineering", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 10, 1 January 2021 (2021-01-01), pages 5084, XP093012630, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151067/pdf/ijms-22-05084.pdf> DOI: 10.3390/ijms22105084 *
WENTIAN LUO ET AL: "Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells", NUCLEIC ACIDS RESEARCH, vol. 45, no. 14, 21 August 2017 (2017-08-21), GB, pages 8411 - 8422, XP055543778, ISSN: 0305-1048, DOI: 10.1093/nar/gkx572 *

Also Published As

Publication number Publication date
IL311782A (en) 2024-05-01
JP2024536307A (en) 2024-10-04
WO2023060089A2 (en) 2023-04-13
US20240392262A1 (en) 2024-11-28
EP4413124A2 (en) 2024-08-14
KR20240099249A (en) 2024-06-28
CA3234642A1 (en) 2023-04-13
AU2022358729A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
WO2019006471A3 (en) Novel crispr rna targeting enzymes and systems and uses thereof
WO2018226732A8 (en) Multibiotic agents and methods of using the same
WO2017143042A3 (en) Compositions for enhancing targeted gene editing and methods of use thereof
WO2007124493A3 (en) Methods and compositions for producing recombinant proteins using a gene for trna
EP4293104A3 (en) Cell-free production of ribonucleic acid
WO2014127287A8 (en) Method for in vivo targeted mutagenesis
HRP20070012A2 (en) IMMUNOSTIMULATORY OLIGONUCLEOTIDE MULTIMERS
WO2006034332A3 (en) In vivo incorporation of alkynyl amino acids into proteins in eubacteria
TW200708258A (en) Tobacco compositions
WO2003089618A3 (en) Transposon system and methods of use
HK1206761A1 (en) Nutritive fragments, proteins and methods
WO2004014143A8 (en) Compositions and process for delivering an additive
WO2006105361A3 (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
IL196893A (en) Vertebrate cell or cell line comprising an orthogonal aminoacyl-trna synthetase
WO2006083924A8 (en) 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
WO2023060089A3 (en) Transposases and uses thereof
WO2024073723A3 (en) Anti-cd122 antibodies and uses thereof
TR200400639T4 (en) Anti-freeze proteins, their production and uses
EP2361979A3 (en) Compositions and methods relating to orthogonal ribosome mRNA pairs
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
WO2006127978A3 (en) Compositions and methods for the treatment of cancer
TW200502318A (en) Polymeric crosslinkable compositions containing acetal amides
WO2021231263A3 (en) Nucleic acid amplification methods
WO2005013955A3 (en) Topical composition comprising terbinafine and hydrocortisone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22798022

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2022358729

Country of ref document: AU

Ref document number: 2022358729

Country of ref document: AU

Ref document number: 311782

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024519988

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3234642

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022358729

Country of ref document: AU

Date of ref document: 20221004

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202417031044

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11202402155R

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 2022798022

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022798022

Country of ref document: EP

Effective date: 20240506

WWE Wipo information: entry into national phase

Ref document number: 202280080288.0

Country of ref document: CN